Bo-Shi Duan1, Long-Fei Xie2, Yue Wang3. 1. Department of Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, P.R. China. 2. Department of Biology, University of California, Berkeley, CA, U.S.A. 3. Department of General Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, P.R. China 13514212975@163.com.
Abstract
BACKGROUND/AIM: T-cadherin is a tumor suppressor gene, its predictive value in colorectal cancer (CRC) still remains controversial. In this study, we aimed to evaluate the association between T-cadherin promoter methylation and CRC by performing a meta-analysis. MATERIALS AND METHODS: The relevant literature was searched using the PubMed, Cochrane Library, Web of Science and Google Scholar databases for articles published until December 2016. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). Sensitivity analysis was performed to examine the heterogeneity and funnel plots were constructed to evaluate publication bias. RESULTS: Nine studies, including 488 samples were included in this meta-analysis. The pooled OR of T-cadherin promoter methylation in cancer tissues was 16.73 (95%CI=6.24-44.87), 19.48 (95%CI=5.64-67.31) and 2.23 (95%CI=1.05-4.75) compared to normal tissues, adjacent tissues and premalignant tissues, respectively. The relationship between T-cadherin promoter methylation and clinicopathological features were also analyzed. However, a significant association was not observed between T-cadherin promoter methylation status and gender, tumor stage, and lymph node status (p>0.05). CONCLUSION: The methylation status of T-cadherin promoter was strongly associated with CRC risk. However, T-cadherin promoter methylation may have a limited prognostic value for CRC patients. Copyright
BACKGROUND/AIM: T-cadherin is a tumor suppressor gene, its predictive value in colorectal cancer (CRC) still remains controversial. In this study, we aimed to evaluate the association between T-cadherin promoter methylation and CRC by performing a meta-analysis. MATERIALS AND METHODS: The relevant literature was searched using the PubMed, Cochrane Library, Web of Science and Google Scholar databases for articles published until December 2016. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). Sensitivity analysis was performed to examine the heterogeneity and funnel plots were constructed to evaluate publication bias. RESULTS: Nine studies, including 488 samples were included in this meta-analysis. The pooled OR of T-cadherin promoter methylation in cancer tissues was 16.73 (95%CI=6.24-44.87), 19.48 (95%CI=5.64-67.31) and 2.23 (95%CI=1.05-4.75) compared to normal tissues, adjacent tissues and premalignant tissues, respectively. The relationship between T-cadherin promoter methylation and clinicopathological features were also analyzed. However, a significant association was not observed between T-cadherin promoter methylation status and gender, tumor stage, and lymph node status (p>0.05). CONCLUSION: The methylation status of T-cadherin promoter was strongly associated with CRC risk. However, T-cadherin promoter methylation may have a limited prognostic value for CRC patients. Copyright
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: Marc-Oliver Riener; Elisabeth Nikolopoulos; Alexander Herr; Peter Johannes Wild; Michael Hausmann; Thorsten Wiech; Marzenna Orlowska-Volk; Silke Lassmann; Axel Walch; Martin Werner Journal: Hum Pathol Date: 2008-07-24 Impact factor: 3.466
Authors: Emmi I Joensuu; Wael M Abdel-Rahman; Miina Ollikainen; Salla Ruosaari; Sakari Knuutila; Päivi Peltomäki Journal: Cancer Res Date: 2008-06-15 Impact factor: 12.701
Authors: Shinichi Toyooka; Kiyomi O Toyooka; Kenichi Harada; Kuniharu Miyajima; Prakash Makarla; Ubaradka G Sathyanarayana; Jing Yin; Fumiaki Sato; Narayan Shivapurkar; Stephen J Meltzer; Adi F Gazdar Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: Kevin Flores; Florian Wolschin; Jason J Corneveaux; April N Allen; Matthew J Huentelman; Gro V Amdam Journal: BMC Genomics Date: 2012-09-15 Impact factor: 3.969
Authors: Kornel E Schuebel; Wei Chen; Leslie Cope; Sabine C Glöckner; Hiromu Suzuki; Joo-Mi Yi; Timothy A Chan; Leander Van Neste; Wim Van Criekinge; Sandra van den Bosch; Manon van Engeland; Angela H Ting; Kamwing Jair; Wayne Yu; Minoru Toyota; Kohzoh Imai; Nita Ahuja; James G Herman; Stephen B Baylin Journal: PLoS Genet Date: 2007-07-31 Impact factor: 5.917